TL;DR: Cigna Healthcare modified MM 0578 covering WATS3D (wide-area transepithelial tissue sampling with computer-assisted 3D analysis) for Barrett's esophagus detection, effective December 16, 2025. Here's what changes for billing teams.
Cigna Healthcare updated its coverage policy for WATS3D under policy code MM 0578 in the Cigna system, affecting CPT codes 88104, 88112, 88305, 88312, and 88361. This policy governs how Cigna evaluates WATS3D as an endoscopic tissue sampling method for Barrett's esophagus detection and surveillance. If your practice bills any of these pathology and cytopathology codes for esophageal tissue analysis in Cigna patients, this update applies to you.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Wide-Area Transepithelial Tissue Sampling with Computer-Assisted 3D Analysis (WATS3D) |
| Policy Code | MM 0578 |
| Change Type | Modified |
| Effective Date | December 16, 2025 |
| Impact Level | High |
| Specialties Affected | Gastroenterology, Pathology, General Surgery |
| Key Action | Audit active claims and charge capture for CPT 88104, 88112, 88305, 88312, and 88361 before December 16, 2025 |
Cigna WATS3D Coverage Criteria and Medical Necessity Requirements 2025
The Cigna WATS3D coverage policy under MM 0578 addresses a specific clinical question: is WATS3D a covered method for detecting and surveilling Barrett's esophagus in Cigna members?
WATS3D uses a wide-area brush to collect esophageal epithelial cells. The specimen is then processed and analyzed using computer-assisted three-dimensional imaging. The result is a pathology report — which is where the CPT codes in this policy come in.
The codes under MM 0578 are all pathology and cytopathology codes. CPT 88104 covers cytopathology of fluids, washings, or brushings with smear interpretation — the direct analog of what WATS3D produces. CPT 88112 covers selective cellular enhancement techniques, such as liquid-based slide preparation with interpretation. CPT 88305 is the Level IV surgical pathology code covering gross and microscopic examination. CPT 88312 covers special stains with interpretation, and CPT 88361 covers morphometric analysis for tumor immunohistochemistry markers like Her-2/neu and estrogen and progesterone receptors.
Medical necessity is the central issue with WATS3D billing. Cigna evaluates whether WATS3D — as a sampling method — meets medical necessity standards compared to conventional endoscopic biopsy. The real issue here is that WATS3D is a relatively newer technique, and payers have been slow to establish consistent reimbursement positions. A modification to MM 0578 signals that Cigna is refining where it stands.
If your gastroenterology or pathology practice uses WATS3D alongside standard forceps biopsy, you need to know exactly what Cigna will and won't pay for under this updated coverage policy. Talk to your compliance officer if you're unsure how the updated criteria apply to your specific patient mix before December 16, 2025.
Prior authorization requirements for WATS3D under Cigna vary by plan. Check the patient's specific Cigna plan before scheduling — what applies to a commercial plan may not apply to a Cigna Medicare Advantage plan. If prior authorization is required and you don't get it, you're looking at a claim denial.
Cigna WATS3D Exclusions and Non-Covered Indications
The policy data available for MM 0578 does not include a detailed breakdown of specific exclusions at this time. That itself tells you something. When Cigna modifies a policy without publishing a clean covered/not-covered list, it usually means the criteria are in the body of the policy document — and that the clinical review bar for medical necessity is active and being applied.
This is exactly the pattern Cigna used in its 2024 updates to genetic testing policies. The absence of a simple "covered" checkbox doesn't mean coverage is easy to get. It means your documentation needs to be strong.
For WATS3D specifically, the risk zone is billing CPT 88104 or 88112 for WATS3D specimens when Cigna determines the sampling method wasn't medically necessary over standard biopsy. If your pathology team processes the specimen and bills the code, but the gastroenterologist didn't document why WATS3D was chosen over conventional techniques, you're exposed.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| WATS3D cytopathology — fluids/washings/brushings with smear interpretation | Coverage determination per MM 0578 criteria | 88104 | Medical necessity documentation required |
| WATS3D with liquid-based/selective cellular enhancement slide preparation | Coverage determination per MM 0578 criteria | 88112 | Medical necessity documentation required |
| Surgical pathology — gross and microscopic examination of esophageal tissue | Coverage determination per MM 0578 criteria | 88305 | Standard Level IV pathology; medical necessity criteria apply |
| Special stains with interpretation for esophageal tissue analysis | Coverage determination per MM 0578 criteria | 88312 | Must be medically indicated; documentation required |
| Morphometric analysis/tumor immunohistochemistry | Coverage determination per MM 0578 criteria | 88361 | Less commonly billed in Barrett's surveillance; verify necessity |
Cigna WATS3D Billing Guidelines and Action Items 2025
Here's what your billing team should do before and after the December 16, 2025 effective date.
| # | Action Item |
|---|---|
| 1 | Pull all open and recent claims for CPT 88104, 88112, 88305, 88312, and 88361 billed for Cigna patients with esophageal indications. Do this now — before December 16, 2025. If any of those claims are pending review, the updated MM 0578 criteria may apply when Cigna adjudicates them. |
| 2 | Verify your documentation supports medical necessity for WATS3D specifically. The gastroenterologist's note should explain why WATS3D was used — not just that a brush biopsy was performed. "Barrett's esophagus surveillance" as a standalone diagnosis code is not enough. The clinical record needs to connect the dots. |
| 3 | Check prior authorization requirements for each Cigna plan type in your patient population. Commercial Cigna plans, Cigna Medicare Advantage plans, and employer self-funded Cigna plans can have different prior authorization rules for the same procedure. Treat each plan type separately. |
| 4 | Update your charge capture workflow to flag WATS3D cases for secondary review. If your practice performs WATS3D regularly, build a checkpoint into your charge capture process. Someone on your team should verify that the correct cytopathology code — 88104 or 88112 depending on processing method — is matched to the correct specimen type before the claim goes out. |
| 5 | Train your pathology billing staff on the distinction between 88104 and 88112. These two codes are easy to confuse. CPT 88104 is for smear preparation with interpretation. CPT 88112 covers selective cellular enhancement — which is what liquid-based WATS3D processing uses. Billing the wrong code isn't just a claim denial risk. It's a compliance issue. |
| 6 | For CPT 88361 — morphometric analysis — document the specific marker being analyzed. This code is for tumor immunohistochemistry like Her-2/neu, estrogen receptors, and progesterone receptors. If your team is billing 88361 in the context of Barrett's esophagus surveillance, the clinical rationale needs to be explicit. This code gets scrutinized. |
| 7 | Review any denials that came in under the previous version of MM 0578. A policy modification sometimes creates an appeals window. If you had claims denied under the old criteria and the new criteria are more favorable, talk to your billing consultant about whether a reconsideration request is warranted. |
If your practice has significant WATS3D volume with Cigna patients, loop in your compliance officer before December 16, 2025. The financial exposure from systematically incorrect billing on five pathology codes adds up fast.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for WATS3D Under MM 0578
Covered CPT Codes (When Medical Necessity Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| 88104 | CPT | Cytopathology, fluids, washings or brushings, except cervical or vaginal; smears with interpretation |
| 88112 | CPT | Cytopathology, selective cellular enhancement technique with interpretation (e.g., liquid-based slide preparation) |
| 88305 | CPT | Level IV — Surgical pathology, gross and microscopic examination |
| 88312 | CPT | Special stain including interpretation and report; Group I for microorganisms (e.g., acid fast, methenamine silver) |
| 88361 | CPT | Morphometric analysis, tumor immunohistochemistry (e.g., Her-2/neu, estrogen receptor/progesterone receptor) |
No HCPCS or ICD-10 codes are listed in the MM 0578 policy data. If Cigna issues companion LCD-equivalent guidance or updates the policy to include diagnosis codes, we'll update this post.
Get the Full Picture for CPT 88104
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.